Limited coverage drugs – buprenorphine

Generic name

buprenorphine

Strength

100 mg/0.5 mL, 300 mg/1.5 mL

Form

extended-release subcutaneous injection

 

Special Authority criteria

Approval period

For the management of moderate to severe opioid use disorder in adult patients.

Patients must be induced and clinically stabilized on an equivalent of 8 mg to 24 mg of transmucosal buprenorphine-naloxone for a minimum of seven days.

1 year

Practitioner exemptions

  • None

Special notes

  • Patients are under the care of a health care provider with experience in the diagnosis and management of opioid use disorder
  • As stated in the Health Canada indication, buprenorphine extended-release injection should be used as part of a complete treatment plan that includes counselling and psychosocial support
  •  As stated in the Health Canada indication, buprenorphine extended-release injection must be administered subcutaneously in the abdominal region by a healthcare provider

Special Authority request form(s)